JPRN-jRCT2031230469Not yet recruitingPhase 2
Randomized, Double-Blind Study of AK1830 in Patients with Pain due to Osteoarthritis of the knee.
Kudo Katsuyasu0 sites400 target enrollmentStarted: November 21, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 400
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 40age old to <= 85age old (—)
- Sex
- All
Inclusion Criteria
- •Male or female aged 40 to 85 years at the time of informed consent.
- •-Patient meets American College of Rheumatology Criteria (ACR) for Osteoarthritis of the knee
- •-Patient who fully understands the contents of the study and is competent to give consent.
Exclusion Criteria
- •-Patient has renal, hepatic, cardiac, pancreatic, or metabolic diseases or hematologic abnormality.
- •-Patient is on a current treatment for malignancy or has a history of malignancy within the past 5 years.
- •-Patient who are pregnant or may be pregnant, who wants to be pregnant during the trial period, patients who are nursing. Patient who cannot agree on proper contraception in the patient or the patient's female partner is a pregnant woman.
Investigators
Similar Trials
Completed
Phase 2
Randomized, Double-Blind Study of AK1830 in Patients with Pain due to Osteoarthritis of the knee.JPRN-jRCT2080224985Asahi Kasei Pharma Corporation400
Completed
Phase 2
Randomized, Double-Blind Study of AK1830 in Patients with low back paiow back painJPRN-jRCT2080225352Asahi Kasei Pharma Corporation400
Completed
Phase 2
Follow ups of patients in AK1830 Phase II Studiesosteoarthritis, chronic lumbar painJPRN-jRCT2031210566Kudo Katsuyasu10
Completed
Phase 1
Clinical Pharmacology Study of AK1830 (Drug-Drug Interaction Study in Healthy Men)JPRN-jRCT2051200119Shimizu Tomohito20
Completed
Phase 1
Clinical Pharmacology Study of AK1830 (Drug-Drug Interaction Study in Healthy Men)JPRN-jRCT2051200123Shimizu Tomohito40